PDCD1 and cancer: The reinvigoration of immune reactivity by PD-1 and PD-L1 targeting antibodies toward several cancers has been quite successful; therefore, the enhanced usage of these antibodies as a “backbone” regimen of anticancer combination treatments is likely [9].